dc.contributor.author | Hoyle, M | |
dc.contributor.author | Crathorne, Louise | |
dc.contributor.author | Peters, J | |
dc.contributor.author | Jones-Hughes, T | |
dc.contributor.author | Cooper, Chris | |
dc.contributor.author | Napier, Mark | |
dc.contributor.author | Tappenden, P | |
dc.contributor.author | Hyde, C | |
dc.date.accessioned | 2013-09-30T08:48:07Z | |
dc.date.issued | 2013-04 | |
dc.description.abstract | Colorectal cancer is the third most commonly diagnosed cancer in the UK after breast and lung cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy. Recently, targeted agents have become available including anti-epidermal growth factor receptor (EGFR) agents, for example cetuximab and panitumumab, and anti-vascular endothelial growth factor (VEGF) receptor agents, for example bevacizumab. | en_GB |
dc.identifier.citation | Vol. 17, Issue 14, pp. 1 - 237 | en_GB |
dc.identifier.doi | 10.3310/hta17140 | |
dc.identifier.uri | http://hdl.handle.net/10871/13703 | |
dc.language.iso | en | en_GB |
dc.publisher | NIHR Health Technology Assessment Programme | en_GB |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/23547747 | en_GB |
dc.subject | Angiogenesis Inhibitors | en_GB |
dc.subject | Animals | en_GB |
dc.subject | Antibodies, Monoclonal | en_GB |
dc.subject | Antibodies, Monoclonal, Humanized | en_GB |
dc.subject | Antineoplastic Agents | en_GB |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | en_GB |
dc.subject | Clinical Protocols | en_GB |
dc.subject | Clinical Trials as Topic | en_GB |
dc.subject | Colorectal Neoplasms | en_GB |
dc.subject | Cost-Benefit Analysis | en_GB |
dc.subject | Disease-Free Survival | en_GB |
dc.subject | Great Britain | en_GB |
dc.subject | Humans | en_GB |
dc.subject | Models, Economic | en_GB |
dc.subject | Quality-Adjusted Life Years | en_GB |
dc.title | The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2013-09-30T08:48:07Z | |
dc.identifier.issn | 1366-5278 | |
exeter.place-of-publication | England | |
dc.identifier.journal | Health Technology Assessment | en_GB |